US preventive care panel members hold pharma stocks and receive ethics waivers

STAT reports that federal health officials granted broad ethics waivers to members of the US Preventive Services Task Force, with some panel members holding pharmaceutical shares or running private medical practices. These waivers allow participation despite financial interests that could be affected by panel recommendations.

This raises questions for pharma and healthcare leaders about the impartiality of federal preventive care guidance. Senior executives should monitor for any regulatory or policy changes that could affect how conflicts of interest are managed in health policy bodies.